MedPath

Sonoma Pharmaceuticals

Sonoma Pharmaceuticals logo
🇺🇸United States
Ownership
Public
Established
1999-01-01
Employees
171
Market Cap
$4.4M
Website
http://www.sonomapharma.com
Introduction

Sonoma Pharmaceuticals, Inc. engages in the development and production of hypochlorous acid (HOCl) products for wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company was founded by Hojabr Alimi and Linda Alimi in April 1999 and is headquartered in Boulder, CO.

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

2

FDA:2

Drug Approvals

Deltasone

Approval Date
Nov 2, 2018
FDA

Doxycycline Hyclate

Approval Date
May 23, 2018
FDA

Clinical Trials

No trials found

News

Sonoma Pharmaceuticals' Hypochlorous Acid-Based Acne Products Gain UK Regulatory Approval

Sonoma Pharmaceuticals has secured MHRA registration for its hypochlorous acid-based acne products, which will be distributed through 1,200+ stores of a leading UK pharmacy chain.

Sonoma Pharmaceuticals Gains FDA Clearance for Enhanced Microcyn Hydrogel

Sonoma Pharmaceuticals has received FDA 510(k) clearance for its Microcyn-based hydrogel, enhancing its wound care applications.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.